New Guidelines for Hospital Nausea Treatment

Hospitalists often default to ondansetron for inpatient nausea, but this habit stems more from marketing history than clinical superiority. Dr. Annie Massart, an associate professor at Emory University School of Medicine, recently addressed this issue at SHM Converge. She argued that physicians receive little formal training on the topic, leading to an over-reliance on a single drug class introduced in the 1990s. Her presentation focused on matching specific antiemetics to the underlying physiology of the patient.

Nausea involves complex neuroanatomic pathways that require distinct treatment approaches. The vestibular system signals distress through muscarinic acetylcholine and histamine 1 receptors, while the gastrointestinal tract primarily involves 5-hydroxytryptamine 3 and dopamine receptors. The brain’s vomiting center and chemoreceptor trigger zone rely on overlapping sets of receptors, including those for dopamine, neurokinin-1, and serotonin. Additionally, the cerebral cortex uses gamma-aminobutyric acid and histamine 1 receptors to contribute to the perception of nausea.

Dr. Massart recommended an etiology-centered approach to treatment. Instead of reflexively ordering a single medication, clinicians should identify which pathway drives the symptoms. She stressed the importance of scheduled dosing over as-needed use to maintain consistent receptor blockade. If symptoms persist, she suggested adding a second agent with a different mechanism rather than cycling through individual medications.

Rethinking Cardiac Risks

A significant portion of the talk addressed the fear of QTc prolongation and torsade de pointes. While a single 4-mg IV dose of ondansetron can increase the QTc interval by roughly 16 to 20 milliseconds, newer data suggests the risk of torsade de pointes may be overstated. The 2017 American Heart Association guidelines suggest obtaining a baseline QTc for patients with known risk factors before starting these medications, including older age, female sex, or electrolyte abnormalities.

Haloperidol partially fell out of favor after a 2007 FDA warning, yet its cardiac risk profile appears comparable to serotonin antagonists like ondansetron. Dr. Massart noted that keeping the total daily dose under 5 mg helps to mitigate concerns regarding the monitoring. For metoclopramide, the Food and Drug Administration’s adverse event system shows very few cases of irregular heartbeats, with only five reported cases of torsade de pointes as of 2024.